Overview

Efficacy and Safety of TAK-438 for the Prevention of Recurrent Gastric or Duodenal Ulcers During Therapy of Low-dose Aspirin

Status:
Completed

Trial end date:
2013-04-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy of TAK-438, once daily (QD) compared to AG-1749 (Lansoprazole) in patients with a history of gastric or duodenal ulcer who require long-term therapy of low-dose aspirin.

Phase:

Phase 3

Details

Lead Sponsor:

Takeda

Treatments:

Aspirin
Dexlansoprazole
Lansoprazole